Gilead Sciences' SWOT analysis: HIV giant faces oncology growth, patent cliff

Gilead Sciences, with a $133.6 billion market cap, is focused on diversifying beyond its HIV franchise, particularly as Biktarvy faces loss of exclusivity in 2033; the company is investing heavily in lenacapavir for HIV treatment and prevention, projecting potential peak revenues exceeding $5 billion, and expanding its oncology portfolio with drugs like Trodelvy and anito-cel, targeting a $12 billion CAR T market for multiple myeloma by 2030. While Gilead raised its full-year 2024 guidance after strong Q3 performance, analysts cite competitive pressures in cell therapy and the need to successfully transition patients to new HIV treatments post-Biktarvy as key challenges.

Analysis

Gilead Sciences is navigating a pivotal period, leveraging its strong HIV franchise, characterized by $28.7 billion in last-twelve-months revenue and an InvestingPro "GREAT" financial health score, while strategically preparing for the 2033 patent expiration of its blockbuster drug, Biktarvy. The company demonstrated robust Q3 2024 operational execution, leading to an upward revision of its full-year 2024 guidance by $650 million for product sales and $750 million for operating income, underscored by an impressive 78.3% gross profit margin. Future growth hinges significantly on lenacapavir, a long-acting HIV treatment and PrEP option slated for a summer 2025 launch, with projections of capturing over 60% of the US Descovy/lenacapavir market share by mid-2030 and potential peak revenues exceeding $5 billion. Diversification efforts are centered on its oncology portfolio, particularly Trodelvy and the promising cell therapy anito-cel, which showed a 97% overall response rate in Phase 2 trials for relapsed/refractory multiple myeloma and targets a 2026 launch in a global CAR T market for multiple myeloma anticipated to reach $12 billion by 2030. However, Gilead faces substantial challenges, including managing Biktarvy's loss of exclusivity, navigating a competitive cell therapy landscape with pressures expected to continue into 2025, and overcoming hurdles in PrEP market adoption despite targeting expansion to over 1 million US patients by the mid-2030s. According to InvestingPro, Gilead is trading near its fair value with a P/E ratio of 22.5x.

Key Decisions for Investors

• Investors should closely monitor the launch trajectory of lenacapavir in summer 2025, as its market penetration in HIV treatment and PrEP, aiming for over 60% US Descovy/lenacapavir share by mid-2030 and potentially $5 billion peak revenue, will be critical for mitigating the impact of Biktarvy's 2033 patent expiration.
• The progression of Gilead's oncology pipeline, particularly the clinical data, regulatory pathway, and market positioning of anito-cel against competitors ahead of its targeted 2026 launch, warrants careful observation for signs of successful revenue diversification within the projected $12 billion CAR T market for multiple myeloma.
• Given that Gilead is trading near its InvestingPro fair value estimate (P/E 22.5x) while facing the Biktarvy patent cliff and competitive pressures in cell therapy, investors should carefully weigh the execution risks associated with its pipeline and diversification strategy against the potential long-term growth.